Show simple item record

dc.contributor.advisorİnan, Ümit Übeyt
dc.contributor.authorKaplan, Ümit
dc.date.accessioned2021-05-06T11:57:01Z
dc.date.available2021-05-06T11:57:01Z
dc.date.submitted2006
dc.date.issued2018-08-06
dc.identifier.urihttps://acikbilim.yok.gov.tr/handle/20.500.12812/585917
dc.description.abstractDİABETİ MAKÜLA ÖDEMİK NDE İNTRAVİTREALTRİAMSİNOLON VE BEVACİZUMAB ENJEKSİYONU İLEGRİ LAZER FOTOKOAGÜLASYON TEDAVİD LERİ NNİETKİ KLERİ N KARŞNLİ Nİ ILAŞTIRILMASIDR. ÜMİ KAPLANTÖZETAMAÇ: Diabetik maküla ödemi olan gözlerde modifiye grid lazerfotokoagülasyon, intravitreal triamsinolon ve intravitreal bevacizumabenjeksiyonu tedavilerinin görme keskinliğ ve ödem regresyonu üzerindekiietkilerini incelemek.MATERYAL-METOD: Diabetik maküler ödemi olan 90 hastanı 90nş kapsamı alı . Hastalar 3 gruba ayrı , 1. grup İgözü çalıma na ndı ldı VTAenjeksiyonu grubu, 2. grup intravitreal bevacizumab enjeksiyonu grubu ve3. grup modifiye grid lazer fotokoagülasyon grubu. Ortalama DM süreleri,yaş cinsiyet bakı ndan gruplar arası, mı istatiksel fark yoktu. Hastalar 3 aytakip edildi. Tedavi öncesi, tedaviden sonra 1. hafta, 1. ay ve 3. ay ayrı lıntıoftalmolojik muayene yapı . Düzeltilmişgörme keskinlikleri alı . Tedavildı ndıöncesi, 1. ay ve 3. ay FFA, Mikroperimetri ve HRT-2 makula modülüölçümleri yapı .ldıBULGULAR : Ortalama görme keskinlikleri intravitreal bevacizumabgrubu için tedavi öncesi 0.199±0.14, 1. hafta 0.228±0.15, 1. ay0.242±0.16, 3. ay 0.264±0.16 olarak bulundu. İntravitreal triamsinolongrubu için tedavi öncesi ortalama 0.183±0.10, 1. hafta 0.219±0.14, 1. ay0.249±0.15, 3. ay 0.279±0.17 olarak bulundu. Modifiye grid lazer grubuiçin tedavi öncesi ortalama 0.337±0.16, 1. hafta 0.357±0.17, 1. ay0.389±0.19, 3. ay 0.399±0.19 olarak bulundu. Grup-1 ve grup-2 de 1. haftaIş grup-3'e göre istatistiksel olarak anlamlıve 1. ay görülen görme artıları ydı(p<0,05). Grup-1 de tadavi öncesine göre 1. ay görülen santral 4 dereceortalama makula duyarlı ı ş istatistiksel olarak anlamlı (p=0.014).lı artıığ ydıncı ş ıGrup-1 de gözlenen 1.hafta, 1.ay ve 3. ay göziçi bası artı grup-2 vegrup-3'e göre istatistiksel olarak anlamlıydı (p<0.05). Enjeksiyongrupları endoftalmi, katarakt oluşnda umu, dirençli glokom, dekolman gibikomplikasyonlar gözlenmedi.SONUÇ: İntravitreal bevacizumab enjeksiyonu diabetik maküler ödemtedavisinde grid lazer fotokoagülasyon ve intravitreal triamsinolon asetonidtedavisine benzer sonuçlar vermiş Yan etki insidansı n düş olmasıtir. nı üktekrar uygulamalar açından bir avantaj gibi görünmektedir . Etkisini tamsıolarak değerlendirebilmek için çok merkezli, randomize ve kontrollüaraş rmalar yapıtı lmasıgerekmektedir.II
dc.description.abstractCOMPARISON OF INTRAVITREAL TRIAMSINOLONE,BEVACIZUMAB INJECTION AND GRID LASERPHOTOCOAGULATION TREATMENTS IN DIABETICMACULAR EDEMADR. ÜMİ KAPLANTSUMMARYOBJECTIVE: To evaluate the effects of modified grid laserphotocoagulation, intravitreal triamsinolone and intravitreal bevacizumabinjection treatments on visual acuity and regression of edema.MATERIAL AND METHOD: The 90 eyes of 90 patients with diabeticmacular edema were enrolled in the study. The patients were divided intothree groups; 1st group as intravitreal triamsinolone injection group, 2ndgroup as intravitreal bevacizumab injection group, and 3 rd as modified gridlaser photocoagulation group. The differences of mean duration ofdiabetes mellitus, age, and sex of the groups weren?t statisticallysignificant. The patients were followed for three months. The detailedophtalmological examination was done before the treatment, at the 1stweek, 1st month and the 3rd month after the treatment. The correctedvisual acuities were taken. The FFA, Microperimetry and HRT-2 maculamodule measurements were done before the treatment, at the 1st and the3rd months after the treatment.RESULTS: The mean visual acuities for the intravitreal bevacizumabgroup before the treatment, at the 1st week, 1st month and 3rd month were0.199±0.14, 0.228±0.15, 0.242±0.16, 0.264±0.16, respectively. For theintravitreal triamsinolone group, the mean visual acuities were found asbefore the treatment 0.183±0.10, 1st week 0.219±0.14, 1st monthI0.249±0.15, 3rd month 0.279±0.17. The mean visual acuities for themodified grid laser photocoagulation were before the treatment0.337±0.16, 1st week 0.357±0.17, 1st month 0.389±0.19, and 3rd month0.399±0.19. In the 1st and 2nd groups, increase in vision at 1st week and 1stmonth after the treatment were significantly different from the 3rd group(p<0.05). In the 1st group, the difference in central 4 degree mean macularsensitivity at 1st month was significant statistically from baselinemeasurements (p=0.014). The increase in intraocular pressure at 1st week,1st month and 3rd month in group 1 was significantly different from group-2and group-3 (p<0.05). The complications including endophthalmitis,cataract formation, resistant glaucoma and retinal detachment didn?t occurin the injection groups.CONCLUSION: The results of intravitreal bevacizumab injection intreatment of diabetic macular edema were similar to grid laserphotocoagulation and intravitreal triamsinolone acetonide treatments. Thelow incidence of side effects appears to be an advantage for repeatedapplications of this treatment. Multicenter, randomized, controlledinvestigations are required for evaluation of its effects precisely.IIen_US
dc.languageTurkish
dc.language.isotr
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution 4.0 United Statestr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectGöz Hastalıklarıtr_TR
dc.subjectEye Diseasesen_US
dc.titleDiabetik maküla ödeminde intravitreal triamsinolon ve bevacizumab enjeksiyonu ile grid lazer fotokoagülasyon tedavilerinin etkinliklerinin karşılaştırılması
dc.title.alternativeComparision of intravitreal triamsinolone, bevacizumab injection and grid laser photocoagulation treatments in diabetic macular edema
dc.typedoctoralThesis
dc.date.updated2018-08-06
dc.contributor.departmentGöz Hastalıkları Ana Bilim Dalı
dc.identifier.yokid156408
dc.publisher.instituteTıp Fakültesi
dc.publisher.universityAFYON KOCATEPE ÜNİVERSİTESİ
dc.type.submedicineThesis
dc.identifier.thesisid192808
dc.description.pages97
dc.publisher.disciplineDiğer


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess